LT97201A - Gripo hemagliutinino multivalentinių vakcinų gamybos būdas - Google Patents

Gripo hemagliutinino multivalentinių vakcinų gamybos būdas

Info

Publication number
LT97201A
LT97201A LT97-201A LT97201A LT97201A LT 97201 A LT97201 A LT 97201A LT 97201 A LT97201 A LT 97201A LT 97201 A LT97201 A LT 97201A
Authority
LT
Lithuania
Prior art keywords
sequence
influenza hemagglutinin
multivalent vaccines
producing influenza
new
Prior art date
Application number
LT97-201A
Other languages
English (en)
Other versions
LT4461B (lt
Inventor
Gale Eugene Smith
Franklin Volvovitz
Bethanie E. Wilkinson
Andrei I. Voznesensky
Craig Stanway Hackett
Original Assignee
Protein Sciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27508642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT97201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US08/120,607 priority Critical patent/US5762939A/en
Priority to PT05076536T priority patent/PT1605052E/pt
Priority to BR9510590-5A priority patent/BR9510590A/pt
Priority to EP11159899.1A priority patent/EP2374894B1/en
Priority to HU9801395A priority patent/HUT77921A/hu
Priority to SK1588-97A priority patent/SK286441B6/sk
Priority to DE69534449T priority patent/DE69534449T2/de
Priority to CA2222129A priority patent/CA2222129C/en
Priority to EP95922133A priority patent/EP0833933B1/en
Priority to ES95922133T priority patent/ES2248799T3/es
Priority to AT05076536T priority patent/ATE518000T1/de
Priority to PCT/US1995/006750 priority patent/WO1996037624A1/en
Priority to NZ288026A priority patent/NZ288026A/xx
Priority to AU26925/95A priority patent/AU712776B2/en
Priority to DK05076536.1T priority patent/DK1605052T3/da
Priority to CZ20080037A priority patent/CZ299862B6/cs
Priority to DK95922133T priority patent/DK0833933T3/da
Priority to CNB951979280A priority patent/CN100390289C/zh
Priority to AT95922133T priority patent/ATE304602T1/de
Priority to EP05076536A priority patent/EP1605052B1/en
Priority to DK02076629T priority patent/DK1275726T3/da
Priority to CZ0373897A priority patent/CZ301021B6/cs
Priority to JP53561796A priority patent/JP3757318B2/ja
Priority to US08/453,848 priority patent/US5858368A/en
Priority to IS4620A priority patent/IS4620A/is
Priority to FI974319A priority patent/FI974319A7/fi
Priority to NO975434A priority patent/NO975434L/no
Priority to LT97-201A priority patent/LT4461B/lt
Application filed by Protein Sciences Corporation filed Critical Protein Sciences Corporation
Publication of LT97201A publication Critical patent/LT97201A/lt
Publication of LT4461B publication Critical patent/LT4461B/lt
Priority to HK06106203.4A priority patent/HK1083867B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
LT97-201A 1993-09-13 1997-12-23 Gripo hemagliutinino multivalentinių vakcinų gamybos būdas LT4461B (lt)

Priority Applications (29)

Application Number Priority Date Filing Date Title
US08/120,607 US5762939A (en) 1993-09-13 1993-09-13 Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
DK95922133T DK0833933T3 (da) 1993-09-13 1995-05-26 En vektor samt fremgangsmåde til fremstilling af influenza-hæmagglutinin
CZ20080037A CZ299862B6 (cs) 1993-09-13 1995-05-26 Polypeptid obsahující baculovirový signální peptid
EP11159899.1A EP2374894B1 (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
HU9801395A HUT77921A (hu) 1993-09-13 1995-05-26 Eljárás multivalens influenza hemagglutinin vakcinák előállítására
SK1588-97A SK286441B6 (sk) 1993-09-13 1995-05-26 Vektor na výrobu rekombinantného chrípkového HAO hemaglutinínového proteínu a spôsob výroby hemaglutinínu
DE69534449T DE69534449T2 (de) 1993-09-13 1995-05-26 Vektor und methode zur herstellung von influenza hämagglutinin
CA2222129A CA2222129C (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
EP95922133A EP0833933B1 (en) 1993-09-13 1995-05-26 A vector and method for producing influenza hemagglutinin
ES95922133T ES2248799T3 (es) 1993-09-13 1995-05-26 Vector y procedimiento de produccion de hemaglutinina de virus gripales.
AT05076536T ATE518000T1 (de) 1993-09-13 1995-05-26 Methode für die produktion von multivalenten influenza hämagglutinin vakzinen
PCT/US1995/006750 WO1996037624A1 (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
NZ288026A NZ288026A (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
AU26925/95A AU712776B2 (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
DK05076536.1T DK1605052T3 (da) 1993-09-13 1995-05-26 Fremgangsmåde til at producere multivalente influenzahæmaglutininvacciner
PT05076536T PT1605052E (pt) 1993-09-13 1995-05-26 Método para produzir vacinas multivalentes de hemaglutinina de influenza
EP05076536A EP1605052B1 (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
BR9510590-5A BR9510590A (pt) 1993-09-13 1995-05-26 Processo para produzir vacinas multivalentes de hemoglutinina de gripe.
AT95922133T ATE304602T1 (de) 1993-09-13 1995-05-26 Vektor und methode zur herstellung von influenza hämagglutinin
CNB951979280A CN100390289C (zh) 1993-09-13 1995-05-26 生产流感血凝素多价疫苗的方法
DK02076629T DK1275726T3 (da) 1993-09-13 1995-05-26 Fremgangsmåde til fremstilling af influenzahæmagglutinin-multivalente vacciner
CZ0373897A CZ301021B6 (cs) 1993-09-13 1995-05-26 V podstate cistý, rekombinantní, zralý, glykosylovaný chripkový HAO hemaglutininový protein, vektor pro výrobu rekombinantního HAO hemaglutininového proteinu, zpusob výroby uvedeného proteinu a vakcína obsahující uvedený protein
JP53561796A JP3757318B2 (ja) 1993-09-13 1995-05-26 インフルエンザ血球凝集素多価ワクチンの製造方法
US08/453,848 US5858368A (en) 1993-09-13 1995-05-30 Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein
IS4620A IS4620A (is) 1993-09-13 1997-11-25 Aðferð til framleiðslu á fjölgildum inflúensu hemagglútínín bóluefnum
FI974319A FI974319A7 (fi) 1993-09-13 1997-11-25 Menetelmä monenarvoisten influenssahemaglutiniinirokotteiden valmistamiseksi
NO975434A NO975434L (no) 1993-09-13 1997-11-26 Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
LT97-201A LT4461B (lt) 1993-09-13 1997-12-23 Gripo hemagliutinino multivalentinių vakcinų gamybos būdas
HK06106203.4A HK1083867B (en) 2006-05-29 A method for producing influenza hemagglutinin multivalent vaccines

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/120,607 US5762939A (en) 1993-09-13 1993-09-13 Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
CA2222129A CA2222129C (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
PCT/US1995/006750 WO1996037624A1 (en) 1993-09-13 1995-05-26 A method for producing influenza hemagglutinin multivalent vaccines
CNB951979280A CN100390289C (zh) 1993-09-13 1995-05-26 生产流感血凝素多价疫苗的方法
LT97-201A LT4461B (lt) 1993-09-13 1997-12-23 Gripo hemagliutinino multivalentinių vakcinų gamybos būdas

Publications (2)

Publication Number Publication Date
LT97201A true LT97201A (lt) 1998-09-25
LT4461B LT4461B (lt) 1999-02-25

Family

ID=27508642

Family Applications (1)

Application Number Title Priority Date Filing Date
LT97-201A LT4461B (lt) 1993-09-13 1997-12-23 Gripo hemagliutinino multivalentinių vakcinų gamybos būdas

Country Status (21)

Country Link
US (2) US5762939A (lt)
EP (2) EP1605052B1 (lt)
JP (1) JP3757318B2 (lt)
CN (1) CN100390289C (lt)
AT (2) ATE304602T1 (lt)
AU (1) AU712776B2 (lt)
BR (1) BR9510590A (lt)
CA (1) CA2222129C (lt)
CZ (2) CZ299862B6 (lt)
DE (1) DE69534449T2 (lt)
DK (3) DK1275726T3 (lt)
ES (1) ES2248799T3 (lt)
FI (1) FI974319A7 (lt)
HU (1) HUT77921A (lt)
IS (1) IS4620A (lt)
LT (1) LT4461B (lt)
NO (1) NO975434L (lt)
NZ (1) NZ288026A (lt)
PT (1) PT1605052E (lt)
SK (1) SK286441B6 (lt)
WO (1) WO1996037624A1 (lt)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387373B1 (en) * 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
ATE231917T1 (de) * 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US8026096B1 (en) * 1998-10-08 2011-09-27 Protein Sciences Corporation In vivo active erythropoietin produced in insect cells
CA2355270A1 (en) * 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
EP1196772A2 (en) * 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US6544750B1 (en) 1999-08-17 2003-04-08 Thromgen, Inc. Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
DE19963857A1 (de) * 1999-12-30 2001-07-26 Qiagen Gmbh Primer, insbesondere für Primer-abhängige Nukleinsäure-Syntheseprozesse und Nukleinsäure-Amplifikationsverfahren
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
GB0022969D0 (en) * 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
US20040071733A1 (en) * 2001-02-05 2004-04-15 Hiroshi Takaku Baculovirus vector vaccine
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ATE478137T1 (de) * 2003-06-20 2010-09-15 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
AU2004269320B2 (en) 2003-06-20 2009-12-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US20070160622A1 (en) * 2005-12-07 2007-07-12 Medivas, Llc Method for assembling a polymer-biologic delivery composition
US7527967B2 (en) * 2003-11-25 2009-05-05 Academia Sinica Recombinant baculovirus and virus-like particle
CN103755800B (zh) 2004-02-02 2016-02-24 Ambrx公司 经修饰的人类生长激素多肽与其用途
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
US7342107B2 (en) * 2004-05-27 2008-03-11 Centocor, Inc. Cynomolgus prostate specific antigen
AU2005329405A1 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
CN102532321B (zh) * 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
KR101224781B1 (ko) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
NZ555425A (en) * 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
US7524510B2 (en) * 2005-02-23 2009-04-28 The Uab Research Foundation Alkyl-glycoside enhanced vaccination
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
WO2006133088A2 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
CA2618878C (en) 2005-08-18 2016-06-28 Ambrx, Inc. Compositions of trna and uses thereof
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
JP5178520B2 (ja) * 2005-09-22 2013-04-10 メディバス エルエルシー 固体ポリマー送達組成物およびその使用法
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
PL2368572T3 (pl) * 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
SI1954710T1 (sl) * 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
EP1951890A4 (en) * 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EP2019645A4 (en) * 2006-05-02 2013-03-06 Medivas Llc RELEASE OF OPHTHALMOLOGICAL ACTIVITIES OUTSIDE OR WITHIN THE EYE
CN102258778B (zh) * 2006-05-05 2014-08-13 淡马锡生命科学研究院有限公司 生物分子表面展示及其用途
WO2007133616A2 (en) * 2006-05-09 2007-11-22 Medivas, Llc Biodegradable water soluble polymers
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
PT2064333E (pt) * 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
ES2457527T3 (es) * 2006-09-08 2014-04-28 Ambrx, Inc. ARNt Supresor hibrido en células de vertebrados
WO2008030558A2 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US20100105025A1 (en) * 2006-10-12 2010-04-29 Engelhard Eric K Devices for generating detectable polymers
US20080124710A1 (en) * 2006-10-12 2008-05-29 Engelhard Eric K Devices for generating detectable polymers
WO2008118487A2 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
KR101476472B1 (ko) * 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
CN101784283A (zh) * 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
NZ587108A (en) 2007-11-27 2013-04-26 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
DK2294202T3 (en) * 2008-07-08 2015-08-31 Medicago Inc SOLUBLE RECOMBINANT INFLUENZA ANTIGENES
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
CN102186484A (zh) * 2008-08-13 2011-09-14 梅迪沃什有限公司 Aabb-聚(酯肽)可生物降解聚合物及其使用方法
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
NO2337846T3 (lt) 2008-09-26 2018-06-16
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
US20120237545A1 (en) 2009-05-29 2012-09-20 Norvartis Ag Assays for influenza virus hemagglutinins
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
GB2471093A (en) * 2009-06-17 2010-12-22 Cilian Ag Viral protein expression in ciliates
SI2445928T1 (en) 2009-06-24 2018-05-31 Medicago Inc. HYPER PARTICULARS, SIMILAR VIRUSES OF GRIPE, WHICH HAVE EXPOSED HEMAGLUTININE
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US8810417B2 (en) * 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
SG178918A1 (en) 2009-09-22 2012-04-27 Medicago Inc Method of preparing plant-derived vlps
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED SWINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
IN2012DN06277A (lt) * 2009-12-28 2015-09-25 Dsm Ip Assets Bv
EP2519636B8 (en) * 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
WO2011094363A2 (en) * 2010-01-26 2011-08-04 The Regents Of The University Of Colorado Influenza virus compositions and methods for universal vaccines
NZ602217A (en) * 2010-03-11 2014-08-29 Immune Design Corp Vaccines for influenza
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN102939104A (zh) 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
KR102113512B1 (ko) 2010-06-01 2020-05-22 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
US8513006B2 (en) 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN102023213B (zh) * 2010-09-28 2014-04-02 汕头大学医学院 一种检测流感病毒抗体的荧光微量细胞凝集方法
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
WO2012129295A1 (en) 2011-03-21 2012-09-27 Vaxin Inc. Rapid and prolonged immunologic-therapeutic
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2723801B1 (en) 2011-06-23 2017-01-18 DSM IP Assets B.V. New biodegradable polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP3023790A1 (en) 2011-12-12 2016-05-25 Novartis AG Assay for influenza virus hemagglutinins
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
TWI434933B (zh) * 2012-04-17 2014-04-21 Nat Univ Tsing Hua 抗多型禽流感病毒之ｄｎａ疫苗及其組合物
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2016179099A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2017005880A1 (en) * 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
US10022436B2 (en) 2016-01-11 2018-07-17 Verndari, Inc. Microneedle compositions and methods of using same
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
CN106749554B (zh) * 2017-01-20 2021-01-15 中山大学 一种流感病毒血凝素蛋白的纯化方法
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US10874737B2 (en) 2018-06-01 2020-12-29 Iowa State University Research Foundation, Inc. Influenza nanovaccine
CA3160955A1 (en) 2019-11-12 2021-05-20 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures
CA3190368A1 (en) 2020-08-24 2022-03-03 Natalie ANOSOVA Vaccines against sars-cov-2 infections
MX2023002356A (es) 2020-08-24 2023-03-22 Sanofi Pasteur Inc Vacunas contra la covid-19 con coadyuvantes en emulsion de escualeno que contiene tocoferol.
AU2022361432A1 (en) 2021-10-08 2024-05-23 Sanofi Pasteur Inc. Multivalent influenza vaccines
CA3237139A1 (en) 2021-11-05 2023-05-11 Sanofi Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
CA3237134A1 (en) 2021-11-05 2023-05-11 Timothy ALEFANTIS Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
AU2023320333A1 (en) 2022-08-01 2025-01-16 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
TW202438673A (zh) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 疫苗及相關方法
JP2026506884A (ja) 2023-02-06 2026-02-27 バイカラ セラピューティクス インコーポレイテッド 併用療法および関連方法
WO2024167885A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025006419A1 (en) 2023-06-26 2025-01-02 Flagship Pioneering Innovations Vii, Llc Engineered plasmodia and related methods
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
AU2024297923A1 (en) 2023-07-25 2026-01-22 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
US20250092426A1 (en) 2023-07-25 2025-03-20 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
CN116763915B (zh) * 2023-08-17 2023-11-03 山东兴瑞生物科技有限公司 一种用于治疗和预防流感病毒的多价疫苗
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025128954A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025129034A2 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025129001A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025128943A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025128934A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025128953A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025128936A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029763A (en) * 1974-08-05 1977-06-14 Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing purified neuraminidase antigen and method of using the same
IN150740B (lt) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
EP0349594A4 (en) * 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
WO1995032286A2 (en) * 1994-05-20 1995-11-30 Microgenesys, Inc. Immunogenic carcinoembryonic antigen and methods of use and production

Also Published As

Publication number Publication date
DK1275726T3 (da) 2008-06-23
JP2000513922A (ja) 2000-10-24
IS4620A (is) 1997-11-25
AU712776B2 (en) 1999-11-18
FI974319A0 (fi) 1997-11-25
HUT77921A (hu) 1998-10-28
SK158897A3 (en) 1999-06-11
EP1605052A3 (en) 2008-08-13
EP1605052A2 (en) 2005-12-14
ATE304602T1 (de) 2005-09-15
DE69534449D1 (de) 2006-01-26
DE69534449T2 (de) 2006-07-06
PT1605052E (pt) 2011-10-19
FI974319A7 (fi) 1998-01-22
CZ301021B6 (cs) 2009-10-14
EP0833933B1 (en) 2005-09-14
DK0833933T3 (da) 2005-10-10
US5858368A (en) 1999-01-12
CN100390289C (zh) 2008-05-28
SK286441B6 (sk) 2008-10-07
BR9510590A (pt) 1999-11-30
JP3757318B2 (ja) 2006-03-22
HK1083867A1 (en) 2006-07-14
CN1194005A (zh) 1998-09-23
NO975434D0 (no) 1997-11-26
LT4461B (lt) 1999-02-25
CZ373897A3 (cs) 1999-02-17
ATE518000T1 (de) 2011-08-15
EP0833933A1 (en) 1998-04-08
ES2248799T3 (es) 2006-03-16
CA2222129A1 (en) 1996-11-28
EP1605052B1 (en) 2011-07-27
AU2692595A (en) 1996-12-11
CA2222129C (en) 2010-04-27
NO975434L (no) 1998-01-19
CZ299862B6 (cs) 2008-12-17
US5762939A (en) 1998-06-09
WO1996037624A1 (en) 1996-11-28
DK1605052T3 (da) 2011-11-07
NZ288026A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
PT1605052E (pt) Método para produzir vacinas multivalentes de hemaglutinina de influenza
US6576243B1 (en) Polynucleotide vaccine formula against porcine reproductive and respiratory pathologies
NZ514528A (en) Vectors comprising the sequnece for a respiratory syncytial virus (RSV) F protein with a heterologous signal sequence (HSV I gD) for vaccines
AR086483A2 (es) Vector de expresion, celula huesped, metodo para preparar un polipeptido antigenico, metodo y equipo para la deteccion de un polinucleotido, anticuerpo, metodo de empleo del anticuerpo, y uso para la manufactura de un medicamento para modular la fisiologia o el desarrollo de una celula o celulas de cultivo de tejido
FI102616B (fi) Menetelmä rokotteen valmistamiseksi ihmisen parainfluenssa-viruksen ty yppiä 3 varten ja menetelmässä käytettävä ilmentämisjärjestelmä
HU9603155D0 (en) Papillomavirus vaccines
CA2114636A1 (en) Recombinant plant viral nucleic acids
AU2893495A (en) Modified plant viruses as vectors of heterologous peptides
AU2347997A (en) Synthesis and purification of hepatitis c virus-like particles
ES2072893T3 (es) Endoproteasa kex2 y procedimiento para su produccion.
HUT78070A (hu) Eljárás humán inzulin előállítására
DE69228944D1 (de) Bovines herpesvirus typ 1rekombinantenpolypeptide und vakzine
ATE107701T1 (de) Expression und sekretion von reifem menschlichem beta-interleukin-1 in bacillus subtilis und mittel und verfahren zu deren ausführung.
NZ502626A (en) Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV)
HUT69961A (en) Avirulent anti-rabies vaccine and method for its preparation
EP0271041A3 (en) Atrial peptide derivatives
EP2374894A3 (en) A method for producing influenza hemagglutinin multivalent vaccines
ATE126701T1 (de) Äusseres membranprotein p1 und peptide von haemophilus influenzae typ b.
EP1275726A3 (en) A method for producing influenza hemagglutinin multivalent vaccines
DE3889562D1 (de) Rekombinante Plasmide, die zur Expression von heterologen Proteinen in Bacillus verwendet werden können.
KR940007182A (ko) 재조합 인간 알파 인터페론 발현벡터, 균주 및 이를 이용한 인간 알파 인터페론의 제조방법
CA2229739A1 (en) Recombinant conglutinin and producing method thereof
AU762901B2 (en) Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases
RU97107302A (ru) Способ иммунизации против инфекции, вызываемой вирусом клещевого энцефалита
ES2088371A1 (es) Procedimiento para la produccion en forma recombinante de antigenos de la glicoproteina ge de herpesvirus bovino tipo 1 y su uso en la diferenciacion serologica entre animales infectados y animales vacunados.

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20020526